Business Description
West Pharmaceutical Services Inc
NAICS : 339112
SIC : 3841
ISIN : US9553061055
Description
West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.44 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | 0.41 | |||||
| Interest Coverage | 84.46 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 17.63 | |||||
| Beneish M-Score | -2.85 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.4 | |||||
| 3-Year EBITDA Growth Rate | 17.9 | |||||
| 3-Year EPS without NRI Growth Rate | 19.3 | |||||
| 3-Year FCF Growth Rate | 11.9 | |||||
| 3-Year Book Growth Rate | 16.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 4.45 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 0.32 | |||||
| 9-Day RSI | 3.58 | |||||
| 14-Day RSI | 9.13 | |||||
| 6-1 Month Momentum % | -5.82 | |||||
| 12-1 Month Momentum % | -14.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.34 | |||||
| Quick Ratio | 1.68 | |||||
| Cash Ratio | 0.7 | |||||
| Days Inventory | 85.42 | |||||
| Days Sales Outstanding | 65.18 | |||||
| Days Payable | 44.66 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.25 | |||||
| Dividend Payout Ratio | 0.11 | |||||
| 3-Year Dividend Growth Rate | 5.8 | |||||
| Forward Dividend Yield % | 0.28 | |||||
| 5-Year Yield-on-Cost % | 0.34 | |||||
| 3-Year Average Share Buyback Ratio | 0.2 | |||||
| Shareholder Yield % | 3.3 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 35.69 | |||||
| Operating Margin % | 21.14 | |||||
| Net Margin % | 18.25 | |||||
| FCF Margin % | 12.43 | |||||
| ROE % | 19.08 | |||||
| ROA % | 14.31 | |||||
| ROIC % | 19.43 | |||||
| ROC (Joel Greenblatt) % | 29.91 | |||||
| ROCE % | 20.15 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 43.07 | |||||
| Forward PE Ratio | 45.76 | |||||
| PE Ratio without NRI | 42.83 | |||||
| Shiller PE Ratio | 58.69 | |||||
| Price-to-Owner-Earnings | 47.28 | |||||
| PEG Ratio | 1.95 | |||||
| PS Ratio | 7.84 | |||||
| PB Ratio | 8.53 | |||||
| Price-to-Tangible-Book | 8.95 | |||||
| Price-to-Free-Cash-Flow | 63.34 | |||||
| Price-to-Operating-Cash-Flow | 30.02 | |||||
| EV-to-EBIT | 35.29 | |||||
| EV-to-Forward-EBIT | 35.88 | |||||
| EV-to-EBITDA | 28.55 | |||||
| EV-to-Forward-EBITDA | 28.78 | |||||
| EV-to-Revenue | 7.59 | |||||
| EV-to-Forward-Revenue | 7.56 | |||||
| EV-to-FCF | 61.13 | |||||
| Price-to-Projected-FCF | 3.29 | |||||
| Price-to-DCF (Earnings Based) | 1.35 | |||||
| Price-to-DCF (FCF Based) | 1.99 | |||||
| Price-to-Median-PS-Value | 1.35 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.3 | |||||
| Price-to-Graham-Number | 4.13 | |||||
| Price-to-Net-Current-Asset-Value | 38.52 | |||||
| Earnings Yield (Greenblatt) % | 2.83 | |||||
| FCF Yield % | 1.63 | |||||
| Forward Rate of Return (Yacktman) % | 20.09 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
West Pharmaceutical Services Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 49,955.884 | ||
| EPS (TTM) (MXN) | 121.965 | ||
| Beta | 0 | ||
| Volatility % | 11.16 | ||
| 14-Day RSI | 9.13 | ||
| 14-Day ATR (MXN) | 5.260177 | ||
| 20-Day SMA (MXN) | 5692 | ||
| 12-1 Month Momentum % | -14.82 | ||
| 52-Week Range (MXN) | 5692 - 6627 | ||
| Shares Outstanding (Mil) | 72.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
West Pharmaceutical Services Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
West Pharmaceutical Services Inc Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
West Pharmaceutical Services Inc Frequently Asked Questions
What is West Pharmaceutical Services Inc(MEX:WST)'s stock price today?
The current price of MEX:WST is MXN5692.00. The 52 week high of MEX:WST is MXN6627.00 and 52 week low is MXN5692.00.
When is next earnings date of West Pharmaceutical Services Inc(MEX:WST)?
The next earnings date of West Pharmaceutical Services Inc(MEX:WST) is 2024-10-25 Est..
Does West Pharmaceutical Services Inc(MEX:WST) pay dividends? If so, how much?
The Dividend Yield %  of West Pharmaceutical Services Inc(MEX:WST) is 0.25% (As of Today), Highest Dividend Payout Ratio of West Pharmaceutical Services Inc(MEX:WST) was 0.26. The lowest was 0.08. And the median was 0.2. The  Forward Dividend Yield % of West Pharmaceutical Services Inc(MEX:WST) is 0.28%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers